MBX Biosciences Announced Once-weekly Canvuparatide Achieved The Primary Endpoint With Statistical Significance In Its Phase 2 Avail Trial
Benzinga Newsdesk 1 year ago
BiotechNewsHealth CareGeneral
Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE)Positive findings in bone and kidney
- Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE)
- Positive findings in bone and kidney biomarkers
- All patients completed the 12-week Avail trial and 94% entered the OLE
- Once-weekly canvuparatide was generally well tolerated, with no treatment-related serious adverse events or discontinuations during the 12-week trial
- Preparation underway to initiate Phase 3 trial in 2026